Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post‐Randomization Analysis
Open Access
- 1 August 2025
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71124
Abstract
Background: A low serum testosterone can prolong the time needed for PSA to exceed normal and prompt a work‐up to rule out prostate cancer (PC), delaying diagnosis. We evaluated PC aggressiveness at diagnosis and PC‐specific and all‐cause mortality (PCSM, ACM)‐risk within comorbidity subgroups in patients with low versus normal testosterone. Methods: Between 2005 and 2015, 350 PSA‐screened patients with tumor (T) category1c‐4N0M0 unfavorable‐risk PC were enrolled in a randomized trial and comprised the study cohort. Fine and Gray and Cox multivariable regression analyses were used to evaluate PCSM and ACM risk, respectively, adjusting for age, known PC prognostic factors, randomized treatment arm, and the time‐dependent use of salvage androgen deprivation therapy. An interaction term between the Adult Comorbidity Evaluation‐27 defined comorbidity and low versus normal testosterone was included in the models to enable an assessment of PCSM and ACM risk within comorbidity subgroups in patients with low versus normal testosterone levels at randomization. Results: After a median follow up of 10.20 years, 89 of 350 patients died (25.43%) with 42 of 89 deaths (47.19%) from PC. In patients with no or minimal but not moderate to severe comorbidity, a significant association was observed between low compared to normal testosterone level at randomization and increased PCSM (AHR: 2.70 [95% CI: 1.27, 5.76], p = 0.01) and ACM risk (AHR: 1.90 [95% CI: 1.11, 3.26], p = 0.02). Conclusion: Unlike PSA, multiparametric MRI (mpMRI) images are not influenced by the serum testosterone level; therefore, evaluating whether PCSM can be reduced by incorporating mpMRI into PC‐screening in otherwise healthy men or transgender women with a low serum testosterone level should be considered. Trial Registration: The statisical code used to derive the results from the interaction model for this post randomization analysis can be found in the Supporting Information.Keywords
This publication has 41 references indexed in Scilit:
- TESTOSTERONE AS A PREDICTOR OF PATHOLOGICAL STAGE IN CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2005
- Pretreatment Serum Testosterone Level as a Predictive Factor of Pathological Stage in Localized Prostate Cancer Patients Treated with Radical ProstatectomyEuropean Urology, 2005
- Prostate specific antigen gene regulation by androgen receptorJournal of Cellular Biochemistry, 2004
- Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/mL or lessUrology, 2001
- High‐grade prostate cancer is associated with low serum testosterone levelsThe Prostate, 2001
- Age‐adjusted survival curves with application in the Framingham studyStatistics in Medicine, 1995
- Interexaminer variability of digital rectal examination in detecting prostate cancerUrology, 1995
- Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 MenJournal of Urology, 1994
- Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examinationUrology, 1993
- Assessment of Screening for Prostate Cancer Using the Digital Rectal ExaminationJournal of Urology, 1989